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This work intended to analyze the advertising of medicines requiring medical prescription, divulged into 
three journals of the neurology and cardiology areas addressed to healthcare professionals. The analysis 
was based on current legislation, among other criteria, as well as specific literature. The presence of the 
following items was investigated: registration number, drug name, specific indications, contraindications; 
cautions and warnings; adverse reactions; possible side effects; posology; legibility of technical-scientific 
information and bibliographic references, phrases and/or expressions about the medication benefits, as 
compared to other drugs; safety warnings, healing promises and pictures of people smiling, and the 
quotations confirmation based on bibliographic references. Among the evaluated legal criteria, it was 
observed the absence of legibility in technical-scientific information in 85% of advertisements; absence 
of side effects in 23%; absence of cautions and warnings in 15%; of contraindications in 12.8%; of 
posology in 6.4%; of registration numbers in 2.7% and of the Common Brazilian Denomination/Common 
International Denomination (Denominação Comum Brasileira/Denominação Comum Internacional 
– DCB/DCI) in 0.6%. Out of 130 statements respecting advantages face to others drugs, 23.8% were 
not confirmed and out of 48 divulged safety messages, 41.7% could not be found in quoted references. 
The pictures of people smiling was a resource used in 42.2% of advertisements. Out of 1362 references 
analyzed, 19.7% were not found and 37.1% of quoted affirmations weren’t confirmed.
Uniterms: Medicines/advertising. Medicines/prescription. Medicines/legislation.
Este trabalho objetivou analisar propagandas de medicamentos sujeitos à prescrição, que foram veiculadas 
em três periódicos das áreas de cardiologia e neurologia, dirigidos a profissionais de saúde. A análise 
envolveu critérios baseados na legislação em vigor, além de outros, e das referências bibliográficas. 
Averiguou-se a presença dos seguintes itens: número de registro, nome do fármaco, indicações 
terapêuticas, contra-indicações, cuidados e advertências, reações adversas, efeitos colaterais, posologia, 
legibilidade das informações técnico-científicas e referências bibliográficas, frases e/ou expressões sobre 
vantagens ante outros fármacos, mensagens de segurança, promessas de cura e imagens de pessoas 
sorridentes, além da confirmação das citações com base nas referências bibliográficas. Dentre os critérios 
legais avaliados, observou-se a ausência de legibilidade das informações técnico-científicas em 85% das 
peças promocionais; a ausência dos efeitos colaterais em 23%; a ausência de cuidados e advertências 
em 15%; de contra-indicações em 12,8%; de posologia em 6,4%; do número de registro em 2,7% e 
da Denominação Comum Brasileira/Denominação Comum Internacional (DCB/DCI) em 0,6%. Das 
130 afirmações relativas a benefícios frente a outros fármacos, 23,8% não foram confirmadas; e das 48 
mensagens de segurança veiculadas, 41,7% não tinham respaldo nas referências citadas. As imagens 
de pessoas sorridentes foram recurso usado em 49,2 % das peças promocionais. Das 1.362 referências 
analisadas, 19,7% não foram encontradas e 37,1% das afirmações referenciadas não foram confirmadas.
Unitermos: Medicamentos/publicidade. Medicamentos/prescrição. Medicamentos/legislação.
INTRODUCTION
The commercial promotion of medicines refers to 
“all informative and persuasive activities developed by 
medicines producers, in order to induce their prescription, 
provision, acquisition or utilization” (SOBRAVIME, 
2001).
According to Jesus (2006), the same pharmaceuti­
cal industry which invests millions in research looking 
for the healing of people, invests also very high amounts 
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all over the world in mass media. So that in United States 
in 2004, the American pharmaceutical companies have 
spent about US$57.5 billion in promotional activities 
while, in the same year, such companies spent only 
US$31.5 billion in Research & Development, including 
also funds from the American government; demonstra­
ting so that these companies have spent almost the double 
of their investments in Research & Development of new 
medicines, with advertising of their products (Gagnon, 
Lexchin, 2008).
In Brazil, according some studies, the pharmaceuti­
cal industry spends about 25% of their global invoicing in 
advertising and correlate activities (Barros, Joany, 2002). 
Other studies make reference to spends varying from 20 to 
40% of the invoicing, representing the double or triple of 
the amount destined to investigation and development of 
new drugs (Barros, 2004; Câmara dos Deputados, 2000).
According to Temporão (1986), the pharmaceutical 
propaganda effectively achieves a change in the physi­
cians’ standard of prescription, besides to be conside­
red, for many times, as their main source of therapeutic 
updating. Therefore, the pharmaceutical industry utilizes 
diverse techniques, such as the support of multiple medi­
cal congresses; the regular visitation to physicians by the 
pharmaceutical representatives (the “reps”), with ample 
distribution of free samples, gifts and printed material; 
beyond continuous advertising in specialized magazines 
and journals (Barros, 1995; Hodges, 1995; Lexchin, 1993; 
Temporão, 1986; Zipkin, Steinman, 2005).
As an attempt to change the standard of medicines 
consumption, the pharmaceutical companies make use 
of different forms of advertising addressed as to outsider 
public, as to healthcare professionals. Thereby, their 
commercial messages achieve an extensive range of 
professionals and people within the healthcare area, from 
physicians and pharmacists up to drugstore owners and 
patients, attaining so to decisively influence the medici­
nes prescription, sale and consumption. (Pizzol, Silva, 
Schenkel, 1998).
There are studies evidencing the existence of a di­
rect relationship between the more advertised medicines 
in medical journals and magazines, and the frequency of 
their prescription by physicians (Barros, 2000; Krupa, 
Vener, 1985).
According to Pizzol, Silva and Schenkel (1998), 
considering the possible impact of advertising on the­
rapeutic practices, it should be expected that medicines 
advertising had always good quality, providing important 
and reliable information about the advertised product. In 
addition, another study has concluded that 50% of adver­
tisements in medical journals do not present the warnings 
and precautions respecting the use of respective products, 
and 40% of them do not include neither contraindications, 
nor adverse reactions (Barros, Joany, 2002), being so in 
complete disagreement with the ethical criteria for me­
dicines advertising that was proposed by WHO (World 
Health Organization), to assure consumers’ safety and 
rights (WHO, 1988).
The importance of medicines advertising as incen­
tive for their consumption is proven by the enormous 
amounts destined by pharmaceutical industry for this 
purpose (Pizzol, Silva, Schenkel, 1998). Fagundes et al. 
(2007), in a research developed with physicians, in order 
to examine the way they perceive the effects of adverti­
sing on their professional activity, verified that 68% of 
them believe in the direct influence of advertising on their 
prescription habits; in addition, 14% of them affirmed 
to prescribe specific medicines as a function of rewards 
reception from the respective pharmaceutical companies. 
Other studies evaluating the physicians’ behavior face 
to pharmaceutical industry promotions and advertising, 
have proven the influence of these persuasion strategies 
on the physicians’ prescription habits (Castresana, Mejia, 
Aznar, 2005).
Any form of medicines divulgence, due to inherent 
characteristics of these products resulting from a direct 
relationship between health and disease, should be su­
pported by ethical and legal groundings, presenting not 
only the benefits and qualities of the advertised product, 
but also its risks, precautions of use and contraindications, 
contributing so for the rational use of medicines and an 
improvement in population health. However, there is an 
evident conflict of interests and objectives between the 
medicines producers and distributors, whose target is to 
increase their own profits, and the medicines advertising 
regulatory organs, whose main objective consists in sup­
port and promote the health assistance improvement, by 
means of the rational use of medicines (Resener, 2004).
Studies developed in Russia about medical magazi­
nes advertising, pointed out that in only 40% of advertise­
ments, the generic name of medicines appeared; in 45%, 
some indication was mentioned; in 11%, warnings and 
contraindications were mentioned; in 5%, the pharmaco­
logical interactions were presented; and only in 2%, the 
references were presented. The study discusses the little 
access of physicians to safe information sources, and con­
cludes that pharmaceutical advertising does not provide 
the basic information for a competent prescription, poin­
ting out the necessity of governmental regulation, once 
the Ethical Criteria for Promotion of Medicines, published 
by WHO, are not followed voluntarily (Vlassov et al., 
2001).
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Mejia and Avalos (2001), analyzing medicine ad­
vertising pieces addressed to physicians, observed that 
adverse reactions, warnings and contraindications were 
absent of such promotional material in all evaluated adver­
tisements. Besides, out of a total of 131 quoted references, 
60 (46%) were incorrectly listed and, because of that, it 
was not possible to have access to them. Out of the 71 
correctly listed pieces, 49 (69%) were not found into four 
large medical bookstores of Buenos Aires. The 22 found 
references were revised and in 12 of them, the objective 
of these researches coincided with the established in the 
advertisements.
Many professionals rely on the sponsorship from 
pharmaceutical industry, in the same way as medical ma­
gazines rely in experiments sponsored by pharmaceutical 
companies, despite the consequent conflict of interests and 
evidences that sponsored articles are, many times, more 
promotional than other articles (Bero, Galbraith, Rennie, 
1992; Smith, 2003).
The specialized magazines are, almost always, 
edited by the pharmaceutical companies themselves, 
being that in some cases, such companies have their own 
department of communication (house agency), assuring 
total safety to company (Jesus, 2000).
The companies responsible for the elaboration of 
advertising campaigns use as one of their most common 
arguments, the necessity for a given medicine, that is, 
they generate a necessity, create a problem and present the 
medicine as a rapid, safe, effective and riskless solution. In 
a market were many therapeutic options exist for a given 
purpose, the advertising becomes a differential element to 
better sell a product (Kessler et al., 1994).
It is obvious that the divulgence of tendentious 
advertising campaigns, whose objectives are of strictly 
commercial nature, stimulates the growing irrational use 
of medicines. So, it is evident the necessity of reevaluation 
of current legislation, mainly the one about the advertising 
of medicines sold exclusively under prescription, which 
should be addressed exclusively to physicians, and, ne­
vertheless, continues to be addressed by companies to 
outsider public, by means of diverse medias, in a way to 
become them more effective and with lower probability of 
subjective interpretations (Fagundes et al., 2007).
METHODS
This study has analyzed the advertisements of 
medicines subject to medical prescription, divulged by 
3 publications addressed to medical class, in the areas of 
neurology and cardiology.
The Magazine A is a quarterly journal, indexed in 
the EXCERPTA MEDICA, INDEX MEDICUS LATINO-
AMERICANO, LILACS and PSYCINFO databases, and 
classified as Qualis B National for the Medicine Areas I 
and II; the Magazine B is a monthly journal, indexed in 
the Cumulated Index Medicus (NLM ­ Bethesda) ­ ME­
DLINE; EMBASE; LILACS and SCIELO databases and 
classified as Qualis C International for the Medicine Areas 
I and II and the Magazine C is a quarterly journal, inde­
xed in the BIREME-LILACS and classified databases as 
Qualis B National for the Medicine Areas I and II.
The analyzed advertisements were obtained from 
volumes corresponding to the years of 2005 to 2007 of 
Magazines A, B and C.
The advertisements analysis followed to general 
criteria, as follows: 1) a legal criterion, that is, if they were 
in accordance to current legislation and 2) a scientific 
criterion, which has analyzed the reference quotations 
appearing in the advertisements.
The evaluation of legal criterion was based on De­
cree n. 79094/1977 (Brasil, 1977) and Resolution RDC n. 
102/2000 (Brasil, 2000), where the following items have 
been observed: 1) registration number; 2) active principle 
according to DCB or DCI; 3) therapeutic indications; 4) 
contraindications; 5) cautions/precautions and warnings; 
6) adverse reactions; 7) side effects; 8) posology; and 
9) legibility of technical-scientific information (indica­
tions, contraindications, cautions and warnings, adverse 
reactions, side effects and posology) and bibliographical 
references.
Besides to legal criteria, it was also evaluated if the 
advertisements brought phrases and/or expressions about: 
1) advantages face to other drugs; 2) safety messages; 3) 
healing promises; besides 4) images of smiling people.
The analysis of bibliographical references has veri­
fied the following items: 1) type of referenced scientific 
material (books, journal articles and package inserts); 2) if 
the refereed materials were localized; 3) if the references 
were listed according to International Committee of Medi­
cal Journal Editors (ICMJE) and 4) if the information con­
tained in advertisements was faithful to quoted reference.
For the reading of technical-scientific information 
(indications, contraindications, cautions and warnings, 
adverse reactions, side effects and complete posology) 
and bibliographic references, it was utilized a manual 
magnifier with increase of 6 times.
RESULTS AND DISCUSSION
Out of the 2034 pages compounding the analyzed 
publications, 187 (9.2%) were occupied by advertise­
ments. Almost the totality of advertisements (99.9%) 
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occupied a complete page of the respective magazine, and 
6 medicines presented small versions of their ‘package 
insert’ inserted within the respective publication body.
The analyzed issues of Magazine A were composed 
by 212 pages, being that 30 (14.2%) of these pages contai­
ned advertisements and a single small version of package 
insert within the publication body. In every issue of this 
magazine, an average of 7.5 advertisements was found.
The analyzed issues of Magazine B were compo­
sed by 1,493 pages, being that 144 (9.6%) of these pages 
contained advertisements and 5 small versions of package 
insert within the publication body. In every issue of this 
magazine, an average of 12 advertisements was found.
The analyzed issues of Magazine C were composed 
by 329 pages, with advertisements only in the overleaf of 
superior cover and in the obverse and overleaf of the infe­
rior cover, totalizing 12 (3.9%) pages. In every issue of this 
magazine, an average of 3.3 advertisements was found.
It was verified that, besides the significant number 
of pages destined to advertisement, the magazines A and 
B presented advertisements from different pharmaceutical 
companies, while in the magazine C, all advertisements 
were from a single pharmaceutical company. Should 
medical journals divulge pharmaceutical advertising? 
According to Smith (2007), yes they do; because the 
pharmaceutical advertising represents an excellent source 
of funds, contributing so for the magazines financial inde­
pendence. However, it is necessary to be careful to avoid a 
pharmaceutical company acquiring the status of exclusive 
advertiser, in order to preserve the editorial independence 
of these magazines. 
Legal Analysis 
The data of legal analysis are demonstrated at Table 
I. The analyzed items were based on article 3rd, item I of 
General Requisites, at article 13th, item I, clauses “a” to 
‘f” of Requisites for Medicines Sold under Prescription, 
established at RDC n. 102/2000 and at article 94th of De­
cree n. 79094/1977 (Brasil, 2000; 1977).
Table II presents the evaluation of legal criteria 
per journal. It was noticed that, despite the differences 
of indexation of these journals, the quality of divulged 
advertisements is similar.
The trade name has appeared in all advertisements, 
always detached. The DCB has also appeared in all ad­
vertisements, always in background, with font size lower 
than that of trade name, but legible. The emphasis given 
to trade name to reveals the intention to fix in prescriber 
memory the medicine trademark. According to Kotler 
(2000), the advertising is classified into three types: the 
TABLE I – Evaluation of Legal Criteria
EVALUATED ITEMS PRESENCE IN THE 
ADVERTISEMENTS
N %
1 Trade name 187 100
2 Registration number 182 97.3
3 Active principle according to 
DCB or DCI
187 100
4 Indications 187 100
5 Contraindications 163 87.2
6 Caution/Warning 159 85
7 Adverse reactions 160 85.6
8 Side effects 144 77
9 Posology 175 93.6
10 Legibility of information 28 15
TABLE II – Evaluation of legal criteria per journal
LEGAL CRITERIA PRESENCE OF LEGAL CRITERIA
JOURNAL A JOURNAL B JOURNAL C
N° % N° % N/ %
1 Trade name 30 100 144 100 13 100
2 Registration number 27 90 142 98.6 13 100
3 DCB 30 100 144 100 13 100
4 Indications 30 100 144 100 13 100
5 Contraindications 29 96.6 121 84 13 100
6 Caution and Warning 27 90 119 82.6 13 100
7 Adverse reactions 29 96.6 118 81.9 13 100
8 Side effects 26 86.6 118 118.9 0 0
9 Posology 30 100 132 91.6 13 100
10 Legibility 3 10 25 17.4 0 0
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persuasive, the reminder and the informative types; and 
for him, these three forms should be utilized according 
the life cycle stage in which the product is found in the 
market. The emphasis given to trade name is related to 
remember advertising, which is focused in remember the 
product buyers and aims to maintain visible to consumers 
the trademark.
The main infraction (85.6%) appearing in the ad­
vertisements was the presentation of technical-scientific 
information (indications, contraindications, cautions and 
warnings, adverse reactions, side effects and complete 
posology) written in very small fonts, which practically 
precluded their visual reading. In some cases, besides the 
font size, the font color in contrast with paper background 
color complicated too much the comprehension of infor­
mation.
According to article 94th of Decree n. 79094/1977, 
“The labeling, package inserts, labels, flysheets 
or any printed modality referring to products 
treated in this Regulation, will have the di-
mensions necessary to easy visual reading, 
observing the minimum height limit of one milli­
meter and being written in a way to facilitate the 
consumer comprehension” (Brasil, 1977).
Besides, the RDC n. 102/2000, Title I – General 
Requisites, in the article 3rd, item I determines that: 
In advertising, promotional messages and/or 
other practices whose objective is the promo­
tion of medicines, the general requisites should 
be accomplished, without prejudice of those 
particularly established for determined types of 
medicine, being requested:
I – to appear, in Portuguese, in clear and precise 
form, the main contraindication, if any, such as 
registered at National Agency of Health Sur­
veillance (Brasil, 2000).
The analyzed advertisements, therefore, accomplish 
only partially the current norms regulating medicines 
advertising, as they present the required information but 
hamper its access, when presenting it in a non clear way, 
embarrassing the visual reading. The advertisements lose, 
in such a way, the objective to become an informative 
tool for physicians, emphasizing only the elements re­
ally wished to be memorized, such as the medicine trade 
name and some pharmacological actions interesting for 
therapeutics, leaving unperceived, mainly the restrictive 
and negative information presented by the medicine (con­
traindications, cautions and warnings, adverse reactions, 
side effects), which are indispensable for its rational use. In 
addition, the suppression of so important information be­
comes these advertisements deceptive by omission, once 
the manufacturer lays aside the information of essential 
product data, which could lead the consumer (in this case, 
the prescriber) to commit mistakes.
The Code of Consumer Defense (Código de Defesa 
do Consumidor – CDC) determines as basic consumer 
rights (item III of article 6th) “The adequate and clear 
information respecting different products and services, 
with correct quality specification, characteristics, com­
position, quality and price, as well as respecting the pre­
sented risks”. Besides, the article 8th determines that “The 
products and services put in the consumption market will 
not result in risks to consumer health or safety, except for 
those considered normal and foreseeable, resulting from 
the product nature and possession; being obliged the pro­
duct suppliers, under any hypothesis, to give the necessary 
and adequate information respecting it”. Respecting 
to advertising, the CDC establishes that it is prohibited 
all deceptive or abusive advertising (article 37) and 
defines this type of advertising as those that renounced 
to inform about product or service essential data (§ 3rd 
of article 37th) (Brasil, 1990). It is observed that, despite 
to have his rights assured by Law, the consumer is having 
his rights systematically injured, by deceptive and abusive 
advertising.
In the same way, Mejia and Avalos (2001), analyzing 
medicine advertisements addressed to physicians, obser­
ved that adverse reactions, warnings and contraindications 
were absent in all evaluated advertisements.
As for many physicians, the advertising is the sin­
gle source of information respecting medicines (Barros, 
1995), it is observed that this knowledge is effectively 
damaged by the manner of presentation of these reports.
Analysis of other criteria
Table III shows the evaluation of other criteria, 
besides the legal ones. None analyzed advertisement 
presented phrases and/or expressions denoting healing 
promise. In 69.5% of analyzed advertisement, there was 
some type of expression demonstrating advantage respec­
ting to other drug, in 25.7% of advertisements there was 
messages about the medicine safety. The indications of 
advantage over other drugs and the safety messages were 
always accompanied by quotations of articles presenting 
comparative studies. Out of 130 affirmations respecting 
to advantages face other drugs contained in the adver­
tisements, 23.8% were not confirmed. Respecting to 48 
divulged safety messages, 41.7% were not supported by 
references, therefore, they were not ratified.
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The images of people smiling and demonstrating he­
alth represent a resource used in 49.2% of advertisements. 
According to Silva, Barreto and Facin (2006), the images 
shown through advertising, in the majority of cases, are 
produced with specific intentions and, for many times, 
are mere illusions of reality, once they do not represent 
the more frequent physical, psychological, social and 
economical characteristics of people to which they are 
addressed, but on the contrary, they valorize characteris­
tics that are typical of a minority, which difficultly could 
be attained by a common middle citizen. Exactly because 
the low incidence of such characteristics, the difficulty to 
attain them and their exhaustive suggestion in the media, 
they become the aimed ideal of “perfection”. Respecting 
this, Aumont (1993) affirms that images have as their first 
purpose, to assure, reinforce, reaffirm and explicit our 
relationship with the visual world: they perform a role of 
visual discovery and this relationship is essential for our 
intellectual activity. The spectator builds the image and the 
image builds the spectator. This approach consists, before 
everything, in treating the spectator as an active partner 
of the image, emotionally and cognitively; and also as a 
psychic organism on which the image, by its turn, also acts.
Analysis of references
The bibliographical materials referenced in the ad­
vertisements were constituted by: journal articles (87.5%), 
package inserts (7.9%), product monographs (1.3%), 
books (1.2%), filed data (0.9%), and others unidentified 
(1.1%) due to incomplete references.
Out of 1362 references quoted in the advertisements, 
268 (19.7%) were not localized; such material was cons­
tituted by 223 (83.2%) journal articles, 18 (6.7%) product 
monographs, 12 (4.5%) filed data and 15 (5.6%) uniden­
tified materials.
The unidentified materials presented minimum data, 
did not allowing even their classification respecting the 
type of bibliographic material. Generally, the non locali­
zed references omitted some important datum, essential 
for their localization, and were not according to norms 
of International Committee of Medical Journal Editors 
(ICMJE, 2008). Data omission precluding the access to 
information appearing in advertising pieces, puts in check 
their own credibility. In the same way, Spielmans et al. 
(2008), evaluating the accuracy of advertising divulged 
in medical journals, verified that more than a half (50.2%) 
of affirmations done in these advertisements, did not 
provide an accessible source that could be used to check 
their veracity.
The bibliographical material found (80.3%) was 
evaluated to verify if it was in accordance with the quo­
tation done in the respective advertisement. In 62.9% of 
cases, the quotations were confirmed.
Table IV demonstrates the evaluation of quotations 
per type of journal.
It was verified that 37.1% of affirmations appearing 
in the analyzed advertisements were not confirmed by their 
referenced sources; a fact that compromises too much the 
quality of divulged information. Villanueva et al. (2003), 
TABLE III – Evaluation of other criteria per journal
OTHER CRITERIA PRESENCE OF OTHER CRITERIA
JOURNAL A JOURNAL B JOURNAL C
N° % N° % N/ %
1 Advantages face to other drugs 27 90 102 70.8 1 7.7
2 Safety messages 12 40 30 20.8 6 46.2
3 Healing promise 0 0 0 0 0 0
4 Images of smiling people 0 0 88 61.1 4 30.8
TABLE IV – Evaluation of quotations per type of journal 
CONFIRMED NOT CONFIRMED TOTAL
N° % N° % N° %
JOURNAL A 130 69.1 58 30.9 188 100
JOURNAL B 497 59.2 343 40.8 840 100
JOURNAL C 61 92.4 5 7.6 66 100
TOTAL 688 62.9 406 37.1 1094 100
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analyzing advertisements published in six Spanish medi­
cal journals in 1997, observed that 41.1% of promotional 
affirmations were not supported by references. In the 
same way, Lankinen et al. (2004), evaluating medicine 
advertisements divulged in four medical journals, verified 
that 21% of quoted references were not relevant for the 
respective affirmations, concluding that referenced affir­
mations contained in pharmaceutical advertisements could 
present a more scientific image, however, such references 
do not assure the quality of their respective affirmations.
These results demonstrate that many pharmaceutical 
advertisements violate the RDC n. 102 in its article 15th, 
which specifies that “The quotations, tables and other 
illustration extracted from scientific publications and 
utilized in any advertisement, publicity or promotion, 
should be faithfully reproduced and specify the complete 
bibliographical reference” (Brasil, 2000). These ground­
less advertisements violate also the Code of Consumer De­
fense, which establishes at its § 1st of article 37th that “It is 
deceptive any modality of information or communication 
of promotional character entirely or partially fake, or that 
is, by any other mode, even by omission, able to induce 
the consumer in a mistake […]” (Brasil, 1990). Taking it 
into account, the referenced and unconfirmed affirmations 
constitute deceptive advertising, being liable, therefore, 
for applicable legal sanctions.
Usually, physicians do not admit their respective 
prescription habit is subjected, in higher or lower grade, 
to influence from promotional activities promoted by 
pharmaceutical industry, in which substantial resources 
are invested. Particularly addressed to physicians, such 
expenses are, ultimately, defrayed by the consumer, as they 
are inlaid in the products price. So significant expenditures 
(on the order of 20 to 25% of global invoicing) applied 
in advertising could only be explained, by the expected 
return in terms of sales and profits. In the United States, 
just in the year of 2004, US$ 57.5 billion were spent by 
pharmaceutical companies in promotional activities (Gag­
non, Lexchin, 2008).
The advertising inserted into medical journals, 
responsible for their defrayal, was already object of inte­
rest of different foreign studies. One of them intended to 
demonstrate the existing relationship between an increase 
in the prescription rate of a given product, and the respec­
tive number of divulged advertisements. In this study, the 
authors observed that high investments in advertising are 
necessary to successfully achieve high sales levels, for 
a drug that has no precise effect in the improvement of 
some specific psychological conditions (Krupka, Vener, 
1985). On the other hand, it was already verified that a less 
critical attitude from physicians, face to pharmaceutical 
companies promotional strategies, is associated to a low 
quality prescription (Haaijer-Ruskamp, Hemminki, 1993). 
In Brazil, according to Barros (1995), the adver­
tising addressed to physicians succeeds to change their 
prescription habits. Fagundes et al. (2007), developing a 
study with physicians in Brasilia (DF), verified that 68% 
of them believe in the direct influence of advertising on 
prescription and 14% said to prescribe medicines as a func­
tion of rewards reception. Trevisol, Ferreira and Karnopp 
(2007), in a study about medicines advertising developed 
with medicine teachers and students, verified that between 
those teachers, 53.6% considered to be never or rarely 
influenced by the pharmaceutical industry, and 53.7% 
affirmed to believe that their professional colleagues are 
so. Between the students, 43.2% believe that in the future, 
as graduated physicians, they will not or rarely be influen­
ced, however, 42.0% believe that physicians are always or 
frequently influenced. For 41.7% of them, the information 
from pharmaceutical industry representatives is good or 
optimal, in addition, 74.8% reported that pharmaceutical 
industry could contribute for their professional practice.
CONCLUSIONS
Among the legal criteria evaluated in advertise­
ments, it was verified as the main irregularity, the lack 
of legibility in technical-scientific information in 85% of 
cases; in 23%, the omission of side effects; in 15% the 
absence of cautions and warnings; in 12.8% the omission 
of contraindications; in 6.4% the absence of posology; in 
2.7% the lack of registration number; and in 0.6% the ab­
sence of DCB/DCI. In addition, not always true arguments 
were divulged to proclaim product advantages; which 
characterizes a violation of current country legal norms, 
as well as ethical criteria established by WHO.
The marketing strategies utilized in persuasion in­
volved, mainly, affirmations of advantage face other drugs 
and safety messages, which not always reflected the vera­
city of quoted bibliographical support. Besides, another 
much utilized tool was the divulgence of smiling people 
demonstrating health, in order to reinforce the established 
idea respecting the role of medicines in health recovery.
Out of the affirmations appearing in advertisements, 
37.1% were not confirmed by referenced studies, which 
deposes against the quality of divulged information, as 
medicines are not merely a merchandising, but products 
that represent a potential danger if wrongly administered. 
Therefore, their advertisements should have a strictly 
informative character, obeying rigorously the legislation 
and ethics principles, once they could be used by many 
physicians as their single source of therapeutic updating.
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The non accomplishment of current legislation, the 
difficulty and/or impossibility of access to important in­
formation, and the excess of arguments that are not always 
true and/or present ambiguities sometimes, compromise 
the quality of divulged information giving margin to 
different interpretations, and could induce prescription 
mistakes and negatively influence the consumption of 
medicines, becoming irrational their utilization.
Face to these substantiations, in the same way as 
journals keep an editorial council to evaluate the articles 
to be published, they could also keep a team to analyze the 
advertisements to be divulged, correcting possible distor­
tions and collaborating for the reliability of information 
presented in their successive editions.
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